InsiderSignal.AI

InsiderSignal.ai

BCDA - Biocardia, Inc.

Insider Purchase by Altman Peter (Pres, CEO)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Altman Peter, serving as Pres, CEO at Biocardia, Inc. (BCDA), purchased 48,000 shares at $1.25 per share, for a total transaction value of $60,000.00. Following this transaction, Altman Peter now holds 216,762 shares of BCDA.

This purchase represents a 28.00% increase in Altman Peter's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, September 19, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, September 23, 2025, 4 days after the trade was made.

Biocardia, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Altman Peter

Pres, CEO

Peter Altman, PhD, is the President and Chief Executive Officer of BioCardia, Inc. (NASDAQ: BCDA), a Sunnyvale, California-based company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.[[1]](https://www.biospace.com/press-releases/biocardia-ceo-peter-altman-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-in-new-york-city-september-8-10-2025)[[2]](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=229)[[3]](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=247) In this role, he leads the advancement of key programs including the CardiAMP® autologous cell therapy for ischemic heart failure, CardiALLO™ allogeneic mesenchymal stem cell therapy, and delivery technologies like the Helix™ transendocardial delivery catheter, while pursuing FDA and Japan PMDA approvals.[[1]](https://www.biospace.com/press-releases/biocardia-ceo-peter-altman-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-in-new-york-city-september-8-10-2025)[[2]](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=229)[[3]](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=247) Dr. Altman has actively represented BioCardia at major industry events, such as the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, the Alliance Global Partners Virtual Healthcare Showcase in May 2025, and the CSI Focus Devices in Heart Failure Congress in December 2025.[[1]](https://www.biospace.com/press-releases/biocardia-ceo-peter-altman-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-in-new-york-city-september-8-10-2025)[[2]](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=229)[[3]](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=247) As a corporate insider, he recently purchased 48,000 shares of BCDA stock on September 19, 2025, at $1.25 per share, signaling confidence in the company's future.[[4]](https://www.gurufocus.com/news/3117445/insider-buying-peter-altman-acquires-48000-shares-of-biocardia-inc-bcda?mobile=true)[[5]](https://www.investing.com/news/insider-trading-news/altman-peter-president-and-ceo-of-biocardia-buys-60000-in-bcda-93CH-4251370)[[6]](https://www.tradingview.com/news/tradingview:d3562cc2389d0:0-biocardia-ceo-peter-altman-acquires-48-000-shares/)

View full insider profile →

Trade Price

$1.25

Quantity

48,000

Total Value

$60,000.00

Shares Owned

216,762

Trade Date

Friday, September 19, 2025

156 days ago

SEC Filing Date

Tuesday, September 23, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Biocardia, Inc.

Company Overview

No company information available
View news mentioning BCDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/457922

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime